143 related articles for article (PubMed ID: 37722984)
21. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
[TBL] [Abstract][Full Text] [Related]
22. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Motzer RJ; McDermott DF; Escudier B; Burotto M; Choueiri TK; Hammers HJ; Barthélémy P; Plimack ER; Porta C; George S; Powles T; Donskov F; Gurney H; Kollmannsberger CK; Grimm MO; Barrios C; Tomita Y; Castellano D; Grünwald V; Rini BI; McHenry MB; Lee CW; McCarthy J; Ejzykowicz F; Tannir NM
Cancer; 2022 Jun; 128(11):2085-2097. PubMed ID: 35383908
[TBL] [Abstract][Full Text] [Related]
23. CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Navani V; Wells JC; Boyne DJ; Cheung WY; Brenner DM; McGregor BA; Labaki C; Schmidt AL; McKay RR; Meza L; Pal SK; Donskov F; Beuselinck B; Otiato M; Ludwig L; Powles T; Szabados BE; Choueiri TK; Heng DYC
Clin Genitourin Cancer; 2023 Feb; 21(1):106.e1-106.e8. PubMed ID: 35945133
[TBL] [Abstract][Full Text] [Related]
24. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Leung D; Saggi SS; Lee CW; McHenry MB; Motzer RJ
Eur Urol; 2022 Mar; 81(3):266-271. PubMed ID: 34750035
[TBL] [Abstract][Full Text] [Related]
25. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
[TBL] [Abstract][Full Text] [Related]
26. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Saggi SS; McHenry MB; Motzer RJ
ESMO Open; 2020 Nov; 5(6):e001079. PubMed ID: 33246931
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan.
Maeda T; Moriwaki K; Morimoto K; Mo X; Yoshioka T; Goto R; Shimozuma K
Value Health Reg Issues; 2024 Mar; 40():118-126. PubMed ID: 38194896
[TBL] [Abstract][Full Text] [Related]
28. Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings.
Joseph RW; Liu FX; Shillington AC; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Saretsky TL; Pickard AS
Qual Life Res; 2020 Oct; 29(10):2651-2660. PubMed ID: 32405921
[TBL] [Abstract][Full Text] [Related]
29. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.
Shoushtari AN; Friedman CF; Navid-Azarbaijani P; Postow MA; Callahan MK; Momtaz P; Panageas KS; Wolchok JD; Chapman PB
JAMA Oncol; 2018 Jan; 4(1):98-101. PubMed ID: 28817755
[TBL] [Abstract][Full Text] [Related]
30. Predictive Impact of Early Changes in Serum C-Reactive Protein Levels in Nivolumab Plus Ipilimumab Therapy for Metastatic Renal Cell Carcinoma.
Tachibana H; Nemoto Y; Ishihara H; Fukuda H; Yoshida K; Iizuka J; Hashimoto Y; Kondo T; Tanabe K; Takagi T
Clin Genitourin Cancer; 2022 Feb; 20(1):e81-e88. PubMed ID: 34772629
[TBL] [Abstract][Full Text] [Related]
31. Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
Chapman PB; Jayaprakasam VS; Panageas KS; Callahan M; Postow MA; Shoushtari AN; Wolchok JD; Betof Warner A
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34702752
[TBL] [Abstract][Full Text] [Related]
32. Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study.
Oka Y; Matsumoto J; Takeda T; Iwata N; Niimura T; Ozaki AF; Bekku K; Hamano H; Araki M; Ishizawa K; Zamami Y; Ariyoshi N
Int J Clin Pharm; 2024 Jun; 46(3):745-750. PubMed ID: 38632203
[TBL] [Abstract][Full Text] [Related]
33. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
Chan A; Dang C; Wisniewski J; Weng X; Hynson E; Zhong L; Wilson L
Am J Clin Oncol; 2022 Feb; 45(2):66-73. PubMed ID: 34991104
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study).
Tomita Y; Kimura G; Fukasawa S; Numakura K; Sugiyama Y; Yamana K; Naito S; Kabu K; Tajima Y; Oya M
Jpn J Clin Oncol; 2021 May; 51(6):966-975. PubMed ID: 33594427
[TBL] [Abstract][Full Text] [Related]
35. Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study).
Kojima T; Kato R; Sazuka T; Yamamoto H; Fukuda S; Yamana K; Nakaigawa N; Sugino Y; Hamamoto S; Ito H; Murakami H; Obara W
Jpn J Clin Oncol; 2022 Nov; 52(11):1345-1352. PubMed ID: 35920793
[TBL] [Abstract][Full Text] [Related]
36. Adverse Events of Axitinib plus Pembrolizumab Versus Lenvatinib plus Pembrolizumab: A Pharmacovigilance Study in Food and Drug Administration Adverse Event Reporting System.
Matsumoto J; Iwata N; Watari S; Ushio S; Shiromizu S; Takeda T; Hamano H; Kajizono M; Araki M; Nasu Y; Ariyoshi N; Zamami Y
Eur Urol Focus; 2023 Jan; 9(1):141-144. PubMed ID: 35915038
[TBL] [Abstract][Full Text] [Related]
37. Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
McGregor B; Geynisman DM; Burotto M; Porta C; Suarez C; Bourlon MT; Del Tejo V; Du EX; Yang X; Sendhil SR; Betts KA; Huo S
Oncologist; 2023 Jan; 28(1):72-79. PubMed ID: 36124890
[TBL] [Abstract][Full Text] [Related]
38. Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study.
Wells JC; Dudani S; Gan CL; Stukalin I; Azad AA; Liow E; Donskov F; Yuasa T; Pal SK; De Velasco G; Hansen AR; Beuselinck B; Kollmannsberger CK; Powles T; McGregor BA; Duh MS; Huynh L; Heng DYC
Clin Genitourin Cancer; 2021 Aug; 19(4):354-361. PubMed ID: 33863648
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.
George DJ; Spigel DR; Gordan LN; Kochuparambil ST; Molina AM; Yorio J; Rezazadeh Kalebasty A; McKean H; Tchekmedyian N; Tykodi SS; Zhang J; Askelson M; Johansen JL; Hutson TE
BMJ Open; 2022 Sep; 12(9):e058396. PubMed ID: 36104138
[TBL] [Abstract][Full Text] [Related]
40. Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma.
Tomiyama N; Tasaki Y; Hamamoto S; Sugiyama Y; Naiki T; Etani T; Taguchi K; Matsuyama N; Sue Y; Mimura Y; Odagiri K; Noda Y; Aoki M; Moritoki Y; Nozaki S; Kurokawa S; Okada A; Kawai N; Furukawa-Hibi Y; Yasui T
Int J Urol; 2023 Sep; 30(9):754-761. PubMed ID: 37150513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
